Search results
Results from the WOW.Com Content Network
The scientists behind the study focused on sodium-glucose cotransporter-2 (SGLT-2) inhibitors, which they found significantly reduced dementia risk compared with another diabetes drug.
A recent study found that a class of medications called SGLT-2 inhibitors—which does not include Ozempic or similar drugs like Zepbound—significantly lowered the risk of dementia in people ...
2. Alleviates Hunger. Metformin improves how well your cells respond to insulin. This helps regulate your blood sugar levels and manage spikes in insulin that can trigger hunger and food cravings.
It was found that Acarbose appeared to reduce incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose compare to diet and exercise, metformin, placebo, no intervention improved all-cause mortality, reducer or increased risk of cardiovascular mortality, serious or non-serious adverse ...
Metformin-associated lactate production may also take place in the large intestine, which could potentially contribute to lactic acidosis in those with risk factors. [96] The clinical significance of this is unknown, though, and the risk of metformin-associated lactic acidosis is most commonly attributed to decreased hepatic uptake rather than ...
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Smoking has been linked to dementia because it can increase the risk of problems with the heart and blood vessels, the Alzheimer’s Society says. Toxins in cigarettes also cause inflammation ...
Pioglitazone/metformin is indicated as an adjunct to diet and exercise: [medical citation needed] To improve glycemic control in patients with type 2 diabetes, or; For patients who are already treated with a separate combination of pioglitazone and metformin, For patients whose diabetes is not adequately controlled with metformin alone, or